skip navigation

S M L Text size
Home » Resources » Clinical Studies » Sorbinil Retinopathy Trial (SRT)

NEI Clinical Studies

Archived Page

The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.

Sorbinil Retinopathy Trial (SRT)

Purpose | Background | Description | Patient Eligibility | Recruitment Status | Current Status | Results | Publications | Resource Centers | NEI Representative

Purpose

To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.

Background

During the last two decades, vision researchers have studied intensively the role of the enzyme aldose reductase (AR) in diabetic cataract and in other diabetic complications. The potentially damaging effects of AR in diabetes were first discovered in the lens fiber cells. In these cells, the enzyme catalyzes the reduction of high levels of glucose to sorbitol through the polyol pathway and initiates a sequence of events that eventually results in opacification of the lens. Because sorbitol (a sugar alcohol) and fructose (a subsequent product of glucose metabolism) cannot readily diffuse across cell membranes, they become trapped in lens fiber cells. There they accumulate at unusually high levels and exert a significant osmotic stress, causing an influx of water and swelling of the lens fibers. Major electrolytic and osmotic changes then occur that lead to lens opacity.

More recently, the detection of AR in the pericytes of retinal capillaries -- cells that are involved very early in the evolution of diabetic retinopathy -- suggests that this enzyme may also play a role in the pathogenesis of this disorder. Scientists now know that AR is present in nerve tissue, and they speculate that in diabetes it induces the depletion of myo-inositol, which leads to the lessening of nerve conduction velocity in diabetic neuropathy.

Chemicals that inhibit aldose reductase have proved effective in preventing damage to the lens, in preventing thickening of retinal capillary basement membranes in diabetic animals, and in improving nerve conduction velocity values in patients with diabetic neuropathy. Therefore, it is possible that AR inhibitors also may be able to prevent, delay, or halt the development or progression of diabetic retinopathy.

Description

To test this hypothesis, an AR inhibitor developed by Pfizer Inc., sorbinil, was studied in this clinical trial. (Other AR inhibitors underwent study in clinical trials sponsored by Ayerst and Alcon.) Initially, 402 patients were randomized into the double-masked treatment period using a dosage schedule of one 250-mg tablet daily. In 1985, recruitment was voluntarily halted by Pfizer because of several serious hypersensitivity reactions among patients taking sorbinil in clinical trials in the United States and Europe. In November 1985, recruitment resumed, using a titrated dosage schedule of 25 mg daily for 2 weeks, followed by 75 mg daily for 2 weeks, then 250 mg daily for the duration. A total of 497 patients participated in the study.

Followup visits were scheduled weekly for the first 4 weeks, monthly for the next 2 months, and every 3 months thereafter. For patients assigned to the titration protocol, additional visits were made at weeks 5 and 6. A complete history was recorded and a physical examination was conducted every 15 months; electrocardiogram was recorded every 6 months. In addition, patients were cautioned to note any signs of hypersensitivity.

Efficacy visits, scheduled at 9-month intervals after the first visit at 12 months, included fundus photographs, visual acuity examinations according to the Early Treatment Diabetic Retinopathy Study (ETDRS), red blood cell sorbitol measure, and assessment of coronary risk factor classification.

The Sorbinil Retinopathy Trial (SRT) was a unique collaboration between private industry and the Federal government in designing, funding, and conducting a multicenter, randomized clinical trial. Pfizer Inc. supported 10 of the 11 participating Clinical Centers, provided the medication, and funded the Data Coordinating Center and Fundus Photograph Reading Center. The National Eye Institute funded the Policy, Data, and Safety Monitoring Committee and its own participating Clinical Center.

Patient Eligibility

Men and women eligible for the SRT had diabetes for 1 to 15 years and were between ages 18 and 56 at the time of enrollment. They had begun taking insulin before their 41st birthday. Their hemoglobin A1c value was within the diabetic range. On retinal examination, they showed no evidence of or only very mild retinopathy, with no more than five microaneurysms per eye. Women were postmenopausal, sterile, or had an IUD in place.

Patient Recruitment Status

Recruitment began in August 1983 and was completed in May 1986.

Current Status of Study

Completed.

Results

Retinopathy Results:
The percentage of patients whose retinopathy severity grade at maximum followup had worsened by two or more levels was not significantly different between the two groups (28 percent in the sorbinil group and 32 percent in the placebo group). The number of microaneurysms increased at a slightly slower rate in the sorbinil group than in the placebo group, with statistically significant differences at 21 and 30 months. About 7 percent of the patients assigned sorbinil developed hypersensitivity reaction in the first 3 months.

On the basis of these results, it is unlikely that sorbinil administered at a dosage of 250 mg daily for 3 years has a clinically important effect on the course of retinopathy in adults with insulin-dependent diabetes of moderate duration. These data are consistent, however, with a slightly slower progression rate in the microaneurysm count among patients assigned to take sorbinil, a finding of uncertain clinical importance.

Neuropathy Results:
Nearly 30 percent of patients showed worsening of clinical measures of distal symmetric polyneuropathy at maximum followup, with very little difference in rates in the two groups. Nerve conduction was studied in 192 patients. For the median motor, median sensory, and peroneal nerves, there were no benefits in maximum amplitudes over the followup period. For the median motor and median sensory nerves, changes in velocities were not significantly different in the two randomized treatment groups. For the peroneal nerve, at the 30-month and maximum followup visits, the distribution of changes in nerve conduction velocity showed an overall improvement in the sorbinil group and a decline in the placebo group. The difference in distributions was statistically significant. Overall, no evidence was found that the early clinical signs and symptoms of diabetic neuropathy were altered by sorbinil.

Publications

Sorbinil Retinopathy Trial Research Group: The Sorbinil Retinopathy Trial: Neuropathy results. Neurology 43: 1141-1149, 1993.

Sorbinil Retinopathy Trial Research Group: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 108: 1234-1244, 1990.

Resource Centers

Chairman's Office and Fundus Photograph Reading Center
Matthew D. Davis, M.D.
Department of Ophthalmology
University of Wisconsin
610 North Walnut Street, Room 417
Madison, WI 53705-5240
Telephone: (608) 263-6071

Data Coordinating Center
Charles H. Hennekens, M.D.
Brigham and Women's Hospital
Department of Medicine
Division of Preventive Medicine
900 Commonwealth Avenue East
Boston, MA 02215-1204
Telephone: (617) 732-4965
Fax: (617) 731-3843

NEI Representative

Donald F. Everett, M.A.
National Eye Institute
National Institutes of Health
Executive Plaza South, Suite 350
6120 Executive Boulevard, MSC 7164
Bethesda, MD 20892-7164
Telephone: (301) 496-5983
Fax: (301) 402-0528

Last Updated: 10/23/99



Department of Health and Human Services NIH, the National Institutes of Health USA.gov